About Geftinat 250mg Gefitinib Tablet
Find relief with Geftinat 250mg Gefitinib Tablet, a blue-ribbon oncology solution expertly marketed by Natco. This ravishing, enlightened prescription medicine, formulated with Gefitinib, targets EGFR for non-small cell lung cancer (NSCLC) treatment. Suitable for adults and administered orally, each round, white tablet delivers precise 250mg dosage. The pack contains 20 tablets in a blister, promising a life span of 24 months when stored below 30C, protected from light and moisture. Geftinat is hospital-friendly, requires a doctor's prescription, and is proudly made in India. Secure your featured therapy before stocks are ending soon.
Clinical Application and Commercial Usage
Geftinat 250mg Gefitinib Tablet is exclusively recommended for adult patients diagnosed with non-small cell lung cancer (NSCLC), administered under careful hospital supervision. Its commercial application is tailored for oncology centers and hospital pharmacies where precision and reliability are paramount. The application surface is oral, standardized in tablet form, ensuring ease of use. Optimal results are achieved when the dosage is taken consistently as directed by an oncologist, aligning with top-tier patient care protocols within the healthcare sector.
Robust Export and Distribution Network
Geftinat 250mg Gefitinib Tablet boasts a thriving presence in major export markets, especially across India and various international regions. Backed by recognized certifications and compliance, it fulfills Purchase Orders with efficient Transportation and Quick Dispatch protocols. This ensures safe and timely delivery to both main domestic hubs and global destinations, accommodating the needs of hospitals, exporters, suppliers, and trading partners. Dependable packaging and regulated logistics support its universal accessibility for oncology treatments worldwide.
FAQ's of Geftinat 250mg Gefitinib Tablet:
Q: How is Geftinat 250mg Gefitinib Tablet typically administered?
A: Geftinat 250mg is taken orally, once daily, as per the oncologist's instructions, ensuring targeted therapy for non-small cell lung cancer.
Q: What is the primary benefit of using Geftinat 250mg Gefitinib Tablet?
A: The primary benefit is its targeted action as an EGFR inhibitor, offering effective therapy for adult patients with non-small cell lung cancer (NSCLC).
Q: Where should Geftinat tablets be stored for best preservation?
A: The tablets should be stored below 30C, protected from light and moisture, to maintain optimal efficacy over their 24-month life span.
Q: When should Geftinat 250mg be administered for best results?
A: It should be taken at the same time every day, ideally following the oncologist's prescribed guidelines for consistent therapeutic benefit.
Q: What certifications and market approvals support Geftinat's commercial distribution?
A: Geftinat 250mg meets recognized certification standards, ensuring its use and export in both domestic markets across India and key international regions.
Q: How can hospitals and suppliers quickly obtain Geftinat 250mg Gefitinib Tablets?
A: Hospitals and suppliers may place Purchase Orders, benefitting from swift Transportation and Quick Dispatch services for timely restocking.